We verified that ADAM17 is elevated in fibrotic lung disease from three perspectives: clinical patients and in vitro and in vivo studies; and our in vivo and in vitro studies provide the specific mechanisms by which ADAM17 activates PF. Here, ADAM17 is linked to lung disorder.